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Abstract
Emerging data suggests that synthetic lethal interactions between mutated oncogenes/tumor
suppressor genes and molecules involved in DNA damage signaling and repair can be
therapeutically exploited to preferentially kill tumor cells. in this review, we discuss the concept of
synthetic lethality, and describe several recent examples in which this concept was successfully
implemented to target tumor cells in culture, in mouse models, and in human cancer patients.
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Targeting Cancer Genes
Cancer is a collection of different genetic diseases.1,2 During tumor development incipient
cancer cells undergo a multistep mutational process during which they acquire a set of
genetic and/or epigenetic lesions, which ultimately result in the cancerous state.1 These
mutations provide the cancer cell with a set of traits that have been termed the “hallmarks of
cancer”—potential for unlimited proliferation, mitogen-independent proliferation, escape
from apoptotic and anti-proliferative signals, immune evasion, sustained angiogenesis and
tissue invasion and metastasis.1 These cancer phenotypes are thought to be the consequence
of gain of function of oncogenes or loss of function of tumor suppressor genes.3 Due to
recent technological advances such as next generation sequencing, we are beginning to
understand the complex genetic changes that ultimately result in cancerous growth.4-10
Cancer-associated mutations can be classified into (1) so-called “driver” mutations, which
are essential for malignant growth and (2) passenger mutations, which appear to be
functionally less significant.10 Recent large-scale tumor genome re-sequencing efforts have
begun to shed light on the identity and frequency of driver lesions and the signaling
pathways that they are involved in. Although the true number of potential driver lesions still
remains a matter of active debate, it appears that there is a limited number of high-frequency
mutations that can be classified as driver lesions.2,4-10 Analysis of breast and colon tumors,
for example, showed that each individual tumor harbors ~50–80 mutations, with on average
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less than 15 being considered to be driver mutations.8 This small number of driver mutations
present within any individual tumor are believed to affect a finite number of relatively well
conserved “core” signaling pathways, that have been re-wired within cancer cells,2,5,8
including those involved in cell cycle control, DNA damage responses, integrin-mediated
cell adhesion, apoptosis, TGFβ signaling, Wnt/Notch signaling, Hedgehog signaling and Ras
signaling.5 Therapeutic targeting of these re-wired oncogenic signaling networks holds great
promise for cancer therapy.
The driver lesions underlying the oncogenic signaling network state can be further sub-
classified into those that are potentially direct drug targets and others for which
pharmacological manipulation is more difficult. Inhibition of “druggable” driver lesions,
such as the BCR-Abl fusion protein (Imatinib), the mutant or amplified EGF receptor
(Gefitinib, Erlotinib), or HER2 (Trastuzumab) are prime examples of successful therapeutic
targeting of critical signaling molecules in cancer.11-13 In contrast, the development of
inhibitory molecules targeting non-kinase oncogenes, such as Myc and Ras has proven to be
much more difficult, even when enzymes that are responsible for critical post-translational
modifications of these oncogenes, such as those involved in Ras farnesylation are targeted.14
In addition to oncogene addiction, tumor cells commonly display hypersensitivity to tumor
suppressor genes. Studies in genetically engineered mouse models of cancer have shown
that, depending on the tissue of origin, re-expression of p53 in preexisting tumors lacking
p53 induces widespread apoptosis or senescence of these tumors.15-17 However, due to
well-established problems in gene delivery, therapeutic restoration of commonly lost tumor
suppressor genes, such as p53, Rb, ATM, p16INK4A or BRCA1/2 is currently not a viable
option for cancer therapy.
The Concept of Synthetic Lethality
While cancer-driving genetic lesions clearly promote the oncogenic state, they are also
commonly associated with dependencies that are specific to these lesions and absent in
normal non-cancerous cells. In recent years the phenomenon of synthetic lethality, which
has its roots in genetic experiments mainly performed in yeast and fruit flies, has been
successfully revisited in the context of cancer therapy. Two genes are said to interact in a
‘synthetic lethal’ fashion, when mutation of either gene in isolation is compatible with
viability, but simultaneous mutation is lethal.18-24 In an extension of this terminology, two
genes are said to be “synthetic sick,” if simultaneous mutation of two genes reduces cellular
fitness without being lethal.18 Synthetic lethal or sick genetic interactions have been widely
reported for loss of function mutations, but can also involve gain of function mutations.
18,25-27 Thus, the protein products of genes that are in synthetic lethal or sick interactions
with known, non-druggable cancer-driving mutations should represent ideal anti-cancer drug
targets for two reasons: First, a synthetic lethality-driven therapeutic regimen is an elegant
way to indirectly target non-druggable cancer-promoting lesions by virtue of
pharmacological inhibition of druggable synthetic lethal interactors. The second advantage
lies in the exquisite selectivity that should be achievable by exploiting true synthetic lethal
interactions for anti-cancer therapy. By definition, pharmacological abrogation of the protein
product of a gene that is synthetic lethal with a given mutated cancer gene will selectively
kill cancer cells, but will be tolerated by healthy cells that lack the cancer cell-specific
mutation.
Components of the DNA damage response network and the DNA repair pathways are
among the most commonly lost genes in human tumors.28-36 It is thought that these
deficiencies in the DNA damage response contribute to the tumorigenic process by
promoting a ‘mutator’ phenotype that allows the acquisition of additional genetic lesions
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that fuel the process of malignant transformation. On the other hand, based on the concept of
synthetic lethality, these loss of function mutations in the DNA damage response may also
provide ample opportunity to selectively target the tumor. With the advent of new
technologies amenable for high throughput screening, the search for synthetic lethal
interactions in mammalian cells is now becoming feasible. Recent studies performed in
cerevisiae, for example, have shown that for 74 genes that (C) are known to be involved in
the maintenance of genomic stability, 4956 unique synthetic lethal interactions exist.37
These 4956 unique synthetic lethal interactions involve 875 different genes.37 Given the
high degree of conservation between the DNA damage response in yeast and man, it is
tempting to speculate that a similar number of synthetic lethal relationships can be identified
in human cells. In the last five years we have witnessed the first successful translations of
the concept of synthetic lethality into novel cancer treatment strategies.18,38-41
Synthetic Lethality between BRCA1/BRCA2 and PARP1
In a series of recent papers, Ashworth, Jackson, Helleday and colleagues reported a
synthetic lethal interaction between Poly(ADP-ribose) polymerase (PARP1) and the high-
penetrance breast and ovarian cancer susceptibility genes BRCA1 and BRCA238,39 (Fig. 1).
Both BRCA1 and BRCA2-deficient cells display a defect in the error-free homologous
recombination (HR) repair mechanism for DNA double strand breaks (DSBs).42,43 This
defect results in the repair of DSBs by error-prone repair mechanisms, such as single strand
annealing (SSA) and non-homologous end joining (NHEJ), which ultimately results in
increased genomic instability.42,44 PARP1 on the other hand is a critical component of the
base excision repair (BER) mechanism, which is important for the repair of DNA single
strand lesions.43 Farmer et al. and Bryant et al. observed that cells exposed to PARP1
inhibitors formed robust nuclear γ-H2AX foci, suggesting that inhibition of PARP1-
dependent repair processes resulted in the formation of DNA lesions such as DSBs and
collapsed replication forks that are normally repaired by HR.38,39 Wildtype cells, or cells
that were hemizygous null for BRCA1 or BRCA2 displayed only slightly reduced survival
after up to 24 hours of PARP inhibition.39 In contrast, cells that were BRCA1 or BRCA2-
deficient showed a dramatically increased loss of viability after PARP inhibition.39 This
increased death of BRCA1 or BRCA2-deficient cells after PARP inhibition could be
explained by the lack of HR activity in those cells, as evidenced by an absence of PARP1
inhibitor-induced Rad51 foci formation. In contrast, Rad51 foci could readily be detected in
wildtype cells.39 Although alternative error-prone repair processes such as NHEJ and SSA
could, in principle, still be operative in these cells, the presence of large-scale genomic
damage likely results in excessive chromosomal instability and cell death. These findings
strongly suggested that PARP inhibition might be an ideal therapeutic strategy for the
treatment of HR-impaired BRCA1 or BRCA2-deficient cancers, based on a synthetic lethal
interaction between these genes (Fig. 1). Consequently, PARP inhibitors are being rapidly
evaluated in clinical trials.40,42 The first results from a phase I trial involving 60 patients
have recently been reported. The PARP inhibitor Olaparib showed limited adverse effects
and had activity in tumors with BRCA1 or BRCA2 mutations.40 However, these results have
to be taken with some caution, since recent reports using cell culture systems showed that
PARP inhibitor-treated BRCA2-deficient cancer cells acquire resistance through secondary
intragenic deletions in BRCA2, which result in expression of new, HR-competent BRCA2
isoforms.45,46 Furthermore, while PARP1-deficient mice are viable and fertile, they appear
to be predisposed for the development of mammary carcinomas.47,48 This might be an
indication that long-term PARP inhibitor treatment should be avoided.
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Synthetic Lethality between p53 and MK2 in the Context of DNA Damage
The concept of synthetic lethality can also be applied to situations where cells are facing
extrinsic cellular stress, such as that induced by DNA-damaging chemotherapy. The
homozygous loss of a given tumor suppressor gene A might not dramatically increase the
chemosensitivity of tumor cells compared to wildtype cells. However, pharmacological
inhibition of the product of gene B that engages in a synthetic lethal relationship with A
might be detrimental for the survival of these tumor cells following chemotherapy treatment.
Thus, in the context of DNA-damaging anti-cancer therapy, synthetic lethal interactions
might be exploited to selectively sensitize cancer cells to genotoxic stress. These
considerations led us, and others, to explore the effects of combinatorial loss of function
experiments in tumor cells. We started by focusing on cells that were deficient for the
prominent tumor suppressor gene p53, which is lost in approximately 30% of all human
tumors.49 We then identified multiple components of the DNA damage response signaling
network that are synthetic lethal with loss of p53 in the context of DNA damaging
chemotherapy, namely the protein kinases MK2, ATM and Chk2.50,51
The DNA damage signaling response has traditionally been divided into two major
branches: The ATM pathway, acting through the downstream effector kinase Chk2, and the
ATR upstream kinase, acting through Chk1. Some crosstalk exists between the ATM/Chk2
and ATR/Chk1 pathways, particularly when signaling through one pathway is partially or
totally deficient.34,52-55 Normally, these pathways appear to have distinct functions with
only partial functional overlap in response to particular forms of DNA damage especially at
later stages in the cell cycle.56 Different types of genotoxic stress are preferentially
channeled through one or the other of these two pathways. The ATM/ Chk2 pathway is
activated primarily in response to DSBs, such as those formed by topoisomerase-2
inhibitors, while the ATR/Chk1 pathway is activated by bulky DNA lesions induced by UV-
light, and in response to replication fork collapse during S-phase.52,57 We initially identified
MK2, as a downstream effector kinase in the DNA damage response.50,58 MK2 is a
component of the p38 signaling pathway and is activated directly downstream of p38. The
p38/MK2 signaling complex is considered to be a general stress response pathway, which is
activated in response to a variety of stimuli including various toxins, osmotic stress, heat
shock, reactive oxygen species, cytokines and DNA damage.59 Activation of the p38/MK2
complex in response to genotoxic stress depends on the canonical DNA damage response
kinases ATM and ATR, indicating that this general stress response pathway is recruited as
part of the DNA damage response.50,60,61 One prominent target of the DNA damage
effector kinases Chk1, Chk2 and MK2 are members of the Cdc25 family of dual specificity
phosphatases.62 Phosphorylation and inhibition of Cdc25 by Chk1, Chk2 and/ or MK2
ultimately prevents activation of the Cdk-Cyclin com- into S-phase, S-phase pro- plexes that
mediate transition from G1 gression and mitotic entry, thereby establishing G1, intra-S-phase
and 63,64 Other critical targets for G2/M cell cycle checkpoints. MK2-dependent cell cycle
arrest probably exist, but have not yet been reported.
The context-dependent role for MK2 in cell survival following genotoxic stress was
investigated using RNAi-mediated depletion of MK2 in p53-proficient and p53-deficient
settings.50 Knockdown of MK2 dramatically sensitized p53-deficient murine embryonic
fibroblasts (MEFs), and H-RasV12-driven p53-deficient allografts to the cytotoxic effects of
the cross-linking agent cisplatin and the topoisomerase II inhibitor doxorubicin.50 In
contrast, loss of MK2 in p53-proficient cells did not result in increased cell death.50 Further
investigation into the mechanistic details of this synthetic lethal interaction between MK2
and p53 revealed that MK2-depletion dramatically reduced phospho-rylation of Cdc25A and
B, on the same phospho-acceptor sites that are targeted by Chk1 and Chk2. This suggests
that MK2-dependent phosphorylation of Cdc25A/B might be required for functional G1/S
Reinhardt et al. Page 4
Cell Cycle. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and G2/M cell cycle checkpoints in cisplatin or doxorubicin-treated p53-deficient cancer
cells.50 The inability of MK2-depleted p53-deficient cells to execute functional cell cycle
checkpoints following genotoxic stress resulted in mitotic cell death that involved activation
of caspase-3, indicating that the cells were dying by mitotic catastrophe.50,65
Synthetic Lethality between ATM/Chk2 and p53 in the Context of DNA
Damage
The observation that MK2 displays synthetic lethality with p53 prompted us to search for
additional synthetic lethal interactors of p53 in the DNA damage response network. We
chose to limit this analysis to protein kinases, since these are potentially druggable targets.
Analyzing a large panel of human and murine cell lines, we demonstrated that loss of ATM
or Chk2 strongly increased the sensitivity of p53-deficient cells to doxorubicin-induced cell
death.51 This observation is in line with an earlier report indicating that p53−/−;ATM−/−
MEFs are significantly more sensitive to topoisomerase I and II inhibitors than p53-deficient
MEFs with retained ATM function.66 In contrast, loss of ATM or Chk2 in p53-proficient
cells not only failed to increase the cytotoxic response to doxorubicin, but actually made the
cells resistant to chemotherapy.51 Similar observations were made in vivo using allograft
tumors in NCRnu/nu mice and syngeneic transplants of Eμ-myc-driven lymphomas. RNAi-
mediated ATM depletion strongly sensitized p53-deficient H-RasV12-driven allografts and
p53-deficient Eμ-myc lymphomas while ATM depletion in a p53-proficient setting
conferred resistance. We were able to extend these results obtained in cell culture and
mouse models to human cancer patients by analyzing the 10-year survival of a large cohort
of chemotherapy-treated breast cancer patients. Patients with tumors that lost either ATM or
p53 in isolation had a significantly reduced survival after chemotherapy compared to
patients with tumors that displayed normal levels of ATM and p53. Furthermore, those
patients who had wild-type p53 and mutant ATM had the worst prognosis of all, suggesting
that in the setting of a non-mutated form of p53, ATM activity is important for
chemotherapy-induced cytotoxicity. On the other hand, patients with tumors that displayed
dysfunctional ATM/ Chk2 and p53, albeit exceedingly rare, showed increased survival
compared to patients with tumors that had normal ATM and p53 levels.51 These
observations clearly indicate that synthetic lethality, as a conceptual process, is not simply
the synergy of two deleterious alterations. Here, Jiang, Reinhardt et al. demonstrated that
isolated loss of ATM or p53 promotes chemo resistance, while the combined loss of ATM
and p53 results in markedly increased chemo sensitivity—the exact opposite phenotype.51
The mechanism underlying the synthetic lethality between ATM/Chk2 and p53 is
reminiscent of what has been observed for the interaction between MK2 and p53. In
response to doxorubi-cin, ATM-depleted p53 null cells are unable to execute a functional
G2/M cell cycle checkpoint and display features of mitotic catastrophe.51
Abrogation of ATM or Chk2 in p53-proficient cells and tumors resulted in substantially
increased resistance to doxorubicin—the exact opposite effect of the synthetic lethality that
was seen in p53-deficient settings. This surprising observation could be explained by the
finding that loss of ATM in p53-proficient cells dramatically and selectively reduced the
DNA damage-induced expression of the pro-apoptotic target genes Puma and Noxa, while
expression of the cell cycle arrest-mediating p53 targets p21 and Gadd45α was maintained.
Thus, the protective cell cycle arresting function of p53 remains intact in ATM-depleted
cells, while the pro-apoptotic p53 response is selectively blunted. It remains unclear whether
this selective loss of the p53-mediated induction of Puma and Noxa after doxorubicin is a
direct consequence of reduced ATM-mediated phosphorylation of p53 on Ser-15 (Ser-18 in
mouse p53). Given that this site can also be phosphorylated by the two other DNA damage-
activated phosphatidyl-inositol-3-kinase-like protein kinases (PIKKs) ATR and DNA-PKcs
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this might be unlikely. However, the relative contribution of Ser-15 phosphorylation should
be tested using cells from mice in which endogenous p53 has been replaced with the Ser-18
to Ala mutant. If the sole mechanism of doxorubicin resistance in ATM-depleted p53-
proficient tumors is loss of Ser-18 phosphory-lation, then the Ser-18 to Ala mutant should
phenocopy the loss of ATM. Alternatively, ATM might be involved in recruiting p53 to the
promoters of its pro-apoptotic target genes via a mechanism that is independent of direct p53
phosphorylation. This could be tested using chromatin immunoprecipitation assays to
compare the promoter occupancy of p53 substrate genes in ATM-proficient and ATM-
depleted cells and tumors.
Both MK2 and Chk2 activation after doxorubicin exposure requires the presence of
functional ATM.62 The observation that ATM, Chk2 and MK2 display synthetic lethality
with p53 in the context of DNA-damaging chemotherapy, might suggest that synthetic
lethality with p53 is a generalizable feature of all cell cycle checkpoint signaling pathways,
including the ATR/Chk1 branch. In support of this hypothesis, RNAi-mediated Chk1
depletion has been shown to increase the sensitivity of p53-deficient prostate cancer cells to
doxorubicin.67 However, when considering Chk1 as a chemo-sensitizing drug target, care
should be taken to consider the potential adverse effects of such a treatment strategy. There
is an accumulating body of evidence that global Chk1 inhibition using small molecule
inhibitors might be limited by undesired side-effects or the development of secondary
malignancies. Disruption of either ATR or Chk1 in mice, for instance, results in embryonic
lethality.68-70 Furthermore, WAP-Cre-driven conditional loss of Chk1 in mammary
epithelial tissue is lethal in a homozygous setting, and results in progressive DNA damage
and uncontrolled premature mitotic entry in heterozygous animals,71 while Chk1 inhibition
with small molecule inhibitors in cultured human cells leads to severe stress and cell death
even in the absence of additional genotoxic stress.72 In contrast to what has been described
for ATR or Chk1, mice in which ATM, Chk2 or MK2 have been constitutively deleted are
viable.73-75 These observations, together with the data discussed above, strongly suggest
that ATM/Chk2 and MK2 might be safer drug targets, than ATR/Chk1 for the development
of chemo-sensitizing therapies in the treatment of p53-deficient cancers. It remains to be
seen whether loss or inhibition of Chk1 or MK2 in p53-proficient settings promotes chemo-
resistance, similar to what has been described for ATM and Chk2.
Chemosensitivity is Determined Early during Tumor Development
ATM and p53 have been reported as frequently mutated in human cancers. We performed
expression analysis for ATM and p53 on a large panel of diverse human epithelial tumor
specimens and found aberrant expression of ATM and p53 in ~9% and ~29%, respectively.
These numbers are in excellent agreement with recent large-scale lung adenocarcinoma re-
sequencing efforts that have shown ATM and p53 to be mutated in ~8% and ~30% of cases.4
Interestingly, both studies independently demonstrated—with high statistical significance—
that the combined loss of ATM and p53 is an exceedingly rare event.4 There are at least two
possible explanations for the apparent under-representation of combined loss of ATM/Chk2
and p53. Two recent studies have shown that ATM, Chk2 and p53 activation can frequently
be observed in early pre-neoplastic lesions and that these proteins constitute a checkpoint
response to prevent further malignant transformation.36,76 These studies, in conjunction with
data from the recent report by Jiang, Reinhardt et al. suggest that inactivation of ATM, Chk2
or p53 is sufficient to abolish this early tumor checkpoint and allow further progression even
in the face of oncogene-induced replicative stress and DNA damage.51 Hence, loss of either
protein would be selected for and additional losses of components of this checkpoint might
not confer additional selective advantage. However, based on the synthetic lethal interaction
between ATM/Chk2 and p53 in the context of DNA damage described by Jiang, Reinhardt
et al. an alternative explanation for the underrepresentation of combined ATM/Chk2 and
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p53 deficiency in human tumors might be that loss of both ATM/Chk2 and p53
inappropriately sensitized the tumors to the effects of oncogenic stress-induced DNA
damage occurring during tumor evolution, likely as a result of mitotic catastrophe.51 This
hypothesis should be tested in vivo using models in which ATM/Chk2 and p53 can be
inactivated prior to activation of a potent, replicative stress-inducing oncogene, such as mos.
If DNA damage induced by oncogene activation is indeed lethal for incipient tumor cells
that have lost ATM/Chk2 and p53, one would expect a substantially reduced number of
tumors compared to a situation in which ATM/Chk2 or p53 have been lost in isolation.
Synthetic Lethality as a Means to Sensitize Chemo-Resistant Cancers
The data provided by Jiang, Reinhardt et al. strongly suggests that loss of ATM/Chk2 in the
setting of wild-type p53 not only confers resistance to DNA-damaging chemotherapy in
different mouse models of cancer, but also indicates that these mutations in human tumors
are associated with a significantly impaired response to chemotherapy and reduced patient
survival.51 While inhibition of ATM/Chk2 or MK2 in p53-deficient tumors provides an
elegant synthetic lethality-based strategy to sensitize these tumors for DNA-damaging
chemotherapy (Fig. 2), a different approach has to be taken to sensitize inherently
chemotherapy-resistant ATM-deficient tumors with retained p53 function.
In addition to a well-documented role in mediating cell cycle arrest after genotoxic stress,
ATM also mediates DSB repair. There is strong evidence for a role of ATM in HR-mediated
DSB repair,77-80 with a less pronounced effect on NHEJ-mediated DSB repair.78,80-84 Since
ATM-deficient cancer cells with preserved p53 function must repair doxorubicin-induced
DSBs to ensure long-term survival, they likely rely extensively on alternative, error-prone
DSB repair pathways, such as NHEJ to compensate for the HR defect that is present in
ATM-deficient cells. DSB repair by NHEJ involves binding of the non-catalytic subunits
Ku70 and Ku80 as a heterodimer to the free DNA ends, followed by recruitment of the
catalytic subunit DNA-PKcs. DNA-PKcs activity is essential for XRCC4 and Lig4-mediated
re-joining of the broken ends during the NHEJ process.85-88 Data now provided by Jiang,
Reinhardt et al. showed that the DNA-PKcs-dependent NHEJ pathway becomes essential for
the cellular survival of doxorubicin-treated p53 wildtype tumor cells that lack ATM
function.51 A synthetic lethal interaction between DNA-PKcs and ATM in the presence of
doxorubicin-induced DSBs was formally established by the observation that RNAi or small
molecule inhibitor-mediated suppression of DNA-PKcs signaling specifically sensitized
ATM-depleted p53 wild-type cancer cells for doxorubicin-induced cell death both in vitro
and in vivo. In contrast, in the presence of functional ATM, inhibition of DNA-PKcs did not
have a sensitizing effect. Interestingly, when DNA-PKcs was inhibited in p53-deficient
cancer cells no significant doxorubicin sensitization was seen regardless of ATM status.
These observations are in line with a previous report from Gurley et al. who described early
embryonic lethality (E7.5) in ATM−/−;DNA-PKcs−/− double knockout mice.89 These data
strongly suggest that the NHEJ pathway serves as a backup pathway for DSB repair in HR-
deficient cells that have managed to survive by virtue of intact p53 function. This is
strikingly analogous to the role of the HR pathway as a backup pathway for unrepaired
DSBs that result from PARP inhibition, as discussed above. Thus, while isolated loss of
ATM appears to protect cancer cells from genotoxic stress by selectively blunting the pro-
apoptotic p53 response, it renders these cells exquisitely susceptible to DNA-PKcs
inhibition in the context of DNA-damaging chemotherapy. DNA-PKcs-deficient mice are
viable and do not exhibit an increased incidence of tumorigenesis, further suggesting that
DNA-PKcs might be a safe drug target for chemo sensitization of ATM-deficient tumor cells
with retained p53 function (Fig. 2).90
Reinhardt et al. Page 7
Cell Cycle. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Interestingly, a recent report by Callén et al. suggests that inhibition of DNA-PKcs in ATM-
deficient thymocytes protects these cells from ionizing radiation (IR)-induced apoptotic cell
death, which was likely due to a repression of p53-dependent induction of pro-apoptotic
target genes, such as Puma and Noxa.91 At first glance these results are in contrast to what
was reported by Jiang, Reinhardt et al.51 however, these differences may be cell or DNA
damaging-agent specific. Jiang, Reinhardt et al. used MEFs and lymphoma cells that were
experiencing potent oncogenic stress in their analysis and DNA damage was induced by
doxorubi-cin.51 Callén et al. used normal primary T-cells in combination with IR. Since
DNA damage response networks are extensively rewired in cancer cells, these findings lend
further credence to the concept of differential synthetic lethality effects between normal and
transformed cells.
Future Directions
The first applications of the concept of synthetic lethality discussed here are focused on loss
of function mutations in tumor suppressor genes.38,39,50,51 However, there are reports
indicating that the concept of synthetic lethality is applicable to gain of function mutations,
as well.18 Thus, the same principles that were discussed above could be used to determine
patient-specific therapies for tumors that are driven by ‘non-druggable’ lesions, such as Ras
mutation or Myc amplification. The Elledge, Hahn and Gilliland labs recently successfully
applied large-scale RNAi screening technology to look specifically for synthetic lethal
interactors of mutant K-Ras,92,93 and identified the kinase STK33 and Plk1 as potentially
druggable targets in these mutant tumor types.
The major challenge in the area of synthetic lethal approaches to cancer treatment remains
the identification of synthetic lethal pairs, since these interactions are often non-intuitive.
New technologies, such as genome-wide RNAi screening and next generation sequencing of
cell lines and primary tumor samples, in combination with the use of cell lines carrying
well-defined oncogenic lesions, such as activating K-Ras mutations should allow the
systematic search for new synthetic lethal relationships. Newly identified synthetic lethal
interactions could be rapidly evaluated for their potential clinical efficacy using well-
characterized mouse models of cancer providing that they faithfully recapitulate therapeutic
aspects of the human disease.
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Figure 1.
Exploiting the synthetic lethal relationship between PArP1 and BrCA1/2 for the targeted
treatment of HR-deficient human tumors. HR can serve as a backup DNA repair pathway to
resolve DSBs resulting from replication fork collapse. (A) In normal cells, base
modifications are repaired using base excision repair prior to S-phase entry. (B)
Pharmacological inhibition of the base excision repair component PARP1 results in
unrepaired SSBs, which collapse replication forks into DSBs during S-phase. The newly
synthesized sister chromatid can serve as a template for HR-mediated repair in BRCA1/2-
proficient cells. In BRCA1/2-deficient cancer cells HR-mediated repair of PARP inhibitor-
induced DSBs in not available. Instead, error-prone repair pathways, such as NHEJ and SSA
are utilized, which results in progressive genomic instability and ultimately cell death.
Reinhardt et al. Page 14
Cell Cycle. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Exploiting synthetic lethal interactions for the treatment of human cancer. DNA damage
signaling networks commonly show extensive rewiring incancercells.(A)Inp53andATM-
proficient cancer cells primarily promotes apoptosis. Due to a functional proapoptotic ATM-
Chk2-p53- Puma/Noxa signaling axis conventional DNA-damaging chemotherapeutics
should be recommended. (B) Loss of p53 in cancer cells largely abrogates DNA damage-
induced apoptosis. in these cells ATM signaling is re-directed to induce a robust cell cycle
arrest following genotoxic stress. ATM-mediated homologous recombination repair remains
intact in p53-deficient cancer cells. Rewiring of DNA damage-induced ATM signaling
promotes cellular survival in response to DNA damage. Treatment of p53-deficient tumors
should include a combination of conventional DNA-damaging chemotherapy and ATM
inhibitors. (C) Loss of ATM selectively reduces the induction of the pro-apoptotic p53 target
genes Puma and Noxa following genotoxic stress. induction of the cell cycle-regulatory p53
target genes p21 and Gadd45α remains intact allowing ATM-depleted cancer cells to arrest
the cell cycle after DNA damage. ATM-deficient cancer cells with retained p53 expression
depend on the DNA-PKcs-mediated NHEJ pathway to repair chemotherapy-induced DSBs
and maintain genomic stability. Abolishing DNA-PKcs signaling in these cells results in a
dramatically increased sensitivity to DNA-damaging chemotherapy. Treatment of ATM-
deficient tumors with retained p53 expression should include a combination of conventional
DNA-damaging chemotherapy and DNA-PKcs inhibitors. (D) The combined loss of ATM
and p53 precludes the execution of functional cell cycle checkpoints in cancer cells that are
exposed to DNA-damaging agents. This inability to halt progression through the cell cycle
despite the presence of DNA damage ultimately results in mitotic catastrophe. p53 and
ATM-deficient cancer cells should be exquisitely sensitive to treatment with conventional
DNA-damaging chemotherapy.
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